---
layout: default
title: Palivizumab
parent: Model Prediction Only (L5)
nav_order: 442
evidence_level: L5
indication_count: 10
---

# Palivizumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Palivizumab: From RSV Prophylaxis to Benign Neoplasm of Tongue

## One-Sentence Summary

Palivizumab is a monoclonal antibody that neutralises the RSV F protein, and its known clinical role is prevention of respiratory syncytial virus (RSV) infection rather than any confirmed licensed indication in this data pack.
The TxGNN model predicts a very high association score for **Benign Neoplasm of Tongue**, but **no clinical trials or literature currently support this direction**, and the evidence pack's own mechanistic rationale explicitly states there is no biologically plausible link.
This pattern repeats across all ten top-ranked predictions for this drug, suggesting a model artefact rather than a genuine repurposing signal.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not confirmed in this data pack (no MHRA/UK licence on file); known pharmacological target is RSV F protein neutralisation |
| Predicted New Indication | Benign Neoplasm of Tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not confirmed in this pack (`original_moa` is flagged as a data gap), but the evidence pack's own repurposing rationale describes palivizumab as an anti-RSV F protein monoclonal antibody whose only known activity is neutralisation of respiratory syncytial virus — it has no established anti-tumour or cell-proliferation-modulating mechanism.

There is no plausible biological relationship between RSV neutralisation and benign tongue neoplasms. The rationale field for this candidate states directly that the high TxGNN score likely reflects a prediction artefact: palivizumab is not marketed and therefore has sparse connectivity (low node degree) within the underlying knowledge graph, which can inflate similarity-based scores for unrelated diseases.

This same explanation — no mechanistic link, likely KG sparsity artefact — is repeated identically across all ten top-ranked predicted indications for this drug (epiglottis neoplasm, cervical neuroblastoma, testicular tumour, and others), none of which have any oncological rationale connecting back to an antiviral antibody. This consistency across unrelated disease categories reinforces that the signal is not biologically meaningful.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## UK Market Information

Palivizumab currently has no UK marketing authorisations recorded in this data pack (0 licences; market status: not marketed). No product-level licence, dosage form, or approved indication text is available to summarise.

## Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

*Note: Product-specific warnings and contraindications are currently a blocking data gap (DG001) and must be obtained before any safety evaluation can proceed.*

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN score is high, but there are zero supporting clinical trials or literature, no plausible mechanistic link between RSV neutralisation and any of the ten predicted (mostly oncological) indications, and the drug is not currently marketed in the UK. The evidence pack itself attributes the signal to likely knowledge-graph sparsity rather than genuine pharmacological relevance.

**To proceed, the following is needed:**
- Confirmed TFDA/MHRA product warnings and contraindications (blocking data gap DG001)
- Verified original indication(s) and mechanism of action (data gap DG002)
- Independent literature or preclinical rationale connecting RSV-neutralising antibody activity to any oncological pathway, before this candidate is reconsidered
- If no such rationale emerges, this candidate should be deprioritised in favour of higher-evidence signals
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

